Detail
| LncRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 Sequence |
| Ensembl | ENSG00000229807 |
| RefSeq | NR_001564 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | osteosarcoma |
| ICD-0-3 | M9180/3 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | OS tissues, OS cell lines (MG-63, 143B, MHM and SJSA1) |
| Expression Pattern | up-regulated |
| Function Description | XIST expression was significantly upregulated in OS tissues and cell lines and negatively correlated with clinical prognosis.XIST knockdown inhibited cancer cell proliferation and invasion in vitro, inhibited the EMT of OS cells in vitro, and suppressed subcutaneous tumor growth in vivo. Further analysis demonstrated that XIST regulated YAP expression by functioning as a competing endogenous RNA that sponged miR-195-5p in OS cells. XIST directly interacted with miR-195-5p and decreased the binding of miR-195-5p to the YAP 3'UTR, which suppressed the degradation of YAP mRNA by miR-195-5p. |
| Pubmed ID | 29384226 |
| Year | 2018 |
| Title | The expression of LncRNA RP11-87C12.5 is high in newly diagnosed ALL group and low in complete remission ALL group. In B-ALL, the expression of IncRNA RP11-87C12.5 significantly enhances in cCD79a low expression group. In newly diagnosed ALL group, compared with low expression group, lncRNA RP11-87C12.5 high expression group have higer remission rate and relapse rate, but the difference was not statistically significant.Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p. |
| External Links |
| Links for XIST | GenBank HGNC lncrnadb Noncode |
| Links for osteosarcoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.